12-ethoxy-Marchantin A, a new macrocyclic bis-bibenzyl from Marchantia polymorpha L., exerts anti-aging activity through activating MAPKs-dependent Nrf2/HO-1 signaling pathways.

Phytochemicals represent emerging anti-aging therapeutic candidates, with Marchantia polymorpha L. (liverwort) gaining significant attention due to its broad-spectrum pharmacological properties. This plant exhibits remarkable wound-healing and regenerative capabilities, making it a promising candidate for the development of modern anti-aging drugs. In the presented study, 12-ethoxy-Marchantin A (EMA), a new macrocyclic bis-bibenzyl compound, was isolated and identified from M. polymorpha. Using a Lipopolysaccharide (LPS)-induced mouse macrophage RAW264.7 macrophage model, a Caenorhabditis elegans (C. elegans) aging model, and network pharmacology analysis, we systematically investigated the pharmacological mechanisms underlying its anti-aging effects. Our results demonstrated that EMA significantly reduced inflammatory cytokines and nitric oxide (NO) in LPS-stimulated RAW264.7 cells via the nuclear factor erythroid 2-related factor 2 (Nrf2) / heme oxygenase (HO-1) pathway. Mechanistically, EMA triggered a reactive oxygen species (ROS)-mediated mitogen-activated protein kinase (MAPK)-dependent Nrf2 antioxidant signaling cascade. EMA significantly extended the lifespan and enhanced fecundity in the N2 strain of C. elegans, while reducing lipofuscin deposition and ROS levels. Additionally, EMA enhanced oxidative and heat stress resistance in the N2 strain of C. elegans. Network pharmacology revealed that its anti-aging effects may be mediated by MAPKs/Nrf2/HO-1 pathway regulation. Collectively, these findings highlight EMA as a potent anti-aging with therapeutic potential for aging-related conditions.